Sionna Therapeutics, Inc.

NASDAQ:SION

Biotechnology

Healthcare
$2.97 +1.85%

+$0.68 today

Market cap
$134.35M
Beta
1.29
P/E (TTM)
-19.7
EPS (TTM)
-$1.90
52W Low $13.81High $48.45

Volume 0.52M

Average 0.39M

SION Net Income

Bottom-line profit after all expenses, interest, and taxes.

Sionna Therapeutics, Inc.NASDAQ: SION

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$26.78M, compared with -$16.48M a year earlier. Trailing-twelve-month net income was -$85.57M.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$117.85M (-56.6%) for the fiscal year ending Dec 2026, a slowdown from the -22.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.78M-31.0% QoQ
Last fiscal yearDec 2025
-$75.27M-22.0% YoY
LTMMar 2026
-$85.57M-29.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-62.5%-61.6%+0.9 pp
1 year-22.0%-56.6%-34.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(75.27M) USD
Year-over-year change
-22.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How SION compares with its peers on the latest reported figures

  • SION's LTM Mar 2026 net income of -$85.57M is the 4th highest of the 11 companies compared; the peer median is -$135.42M.
  • Its year-over-year change of -29.0% is the 7th highest of 11, against a peer median of -17.4%.
SION Competitors Peer median
Net Income for SION and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$43.31M +168.3%—16.3%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$12.01M +126.6%—3.8%
ARDXArdelyx, Inc.LTM Mar 2026-$58.06M -8.0%—13.6%
SIONSionna Therapeutics, Inc.LTM Mar 2026-$85.57M -29.0%——
JANXJanux Therapeutics, Inc.LTM Mar 2026-$114.48M -47.3%—529.7%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$122.54M -335.9%—612.7%
ABCLAbCellera Biologics Inc.LTM Sep 2026-$148.3M +13.6%—218.5%
IMNMImmunome, Inc.LTM Sep 2026-$282.65M -26.9%——
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$309.11M -37.7%—275986.6%
VERAVera Therapeutics, Inc.LTM Jun 2026-$401.9M -84.1%——
BHVNBiohaven Ltd.LTM Jun 2026-$586.84M +23.5%——
Peer median (excluding SION) -$135.42M-17.4%—218.5%

Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue00668K647K
Gross Profit00(668K)(647K)
Gross Margin————
Research & Development34.61M40.63M57.29M60.26M
Selling, General & Admin6.77M9.71M13.27M28.72M
Operating Expenses41.37M50.33M69.89M88.34M
Depreciation & Amortization122K583K668K647K
EBITDA(40.12M)(46.68M)(61.02M)(74.62M)
EBITDA Margin————
Operating Income(41.37M)(50.33M)(70.56M)(88.98M)
Operating Margin————
Interest Income1.13M2.77M8.17M13.3M
Interest Expense0000
Other Income / Expenses1.13M3.07M8.87M13.71M
Income Before Tax(40.24M)(47.26M)(61.69M)(75.27M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(40.24M)(47.26M)(61.69M)(75.27M)
Net Margin————
EPS (Basic)(0.91)(1.07)(1.40)(1.88)
EPS (Diluted)(0.91)(1.07)(1.40)(1.88)
Weighted Avg Shares44.12M44.12M44.12M39.96M
Weighted Avg Shares (Diluted)44.12M44.12M44.12M39.96M

Sionna Therapeutics, Inc.

NASDAQ:SION

Intrinsic Alpha fair value

Locked

Current Price

$2.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.